AGLink® ADC Conjugation Kit (Biotin, DAR2&4, 1mg)
背景（Background）
Antibody-drug conjugates (ADC) is a type of fast growing anticancer drug. Monoclonal antibody is conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. AGLink® ADC conjugation kit is designed to conjugate mAb with Biotin though site-specific enzymatic reaction.
应用说明（Application）
AGLink® ADC Conjugation Kit (Biotin, DAR2&4, 1mg) is designed to conjugate 1mg mAb with Biotin through site-specific enzymatic reaction.
It is for research use only.
优势特色（Features）
Site-specific conjugation through Fc-glycan with high conjugation efficiency
Uniform DAR value and highly homogeneous ADC products
No need of amino acid sequence engineering
Easy to use: One-pot & One-step
Two options: DAR2 & DAR4 ADC product
存储（Storage）
BoxA: The unopened kit is stable for 12 months from the date of manufacture if stored under temperature ≤ -20°C. The opened kit should be stored according to components table.
BoxB: The unopened kit is stable for 12 months from the date of manufacture if stored under 4°C. The opened kit should be stored according to components table.
Statement of Rights
AGLink products are co-developed by ACROBiosystems Co., Ltd. and Glyco-therapy Biotechnology Co., Ltd. based on Glyco-therapy's conjugation platform (YTConju™) and are not authorized for commercial use. The sale and use of AGLink products doesn't represent any forms of license or authorization of the attached technologies for developing any diagnostic, therapeutic or prophylactic products for commercial purposes.
Note of application
AGLink products are intended for research use only by the Buyer or its users and can not be used for any other purposes, including, but not limited to, use for any clinical diagnostic type use, in vitro or in vivo therapeutic use, prophylactic use, any type of consumption or application to human or animals.
关键字： ADC Conjugation Kit;ADC偶联试剂盒;Biotin;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。